Research programme: pneumococcal vaccine intranasal - Eurocine Vaccines
Latest Information Update: 29 Aug 2023
At a glance
- Originator Eurocine
- Developer Eurocine Vaccines
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pneumococcal infections
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Pneumococcal infections in Sweden (Intranasal) (Eurocine Vaccines pipeline, August 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Pneumococcal-infections in Sweden (Intranasal)
- 17 May 2016 Eurocine Vaccines has patent protection for Immunose™ FLU in Russia, Australia and New Zealand